Ignite Creation Date:
2025-12-24 @ 9:40 PM
Ignite Modification Date:
2025-12-25 @ 7:22 PM
Study NCT ID:
NCT00032032
Status:
COMPLETED
Last Update Posted:
2016-12-01
First Post:
2002-03-08
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D016190', 'term': 'Carboplatin'}, {'id': 'D017239', 'term': 'Paclitaxel'}, {'id': 'D011878', 'term': 'Radiotherapy'}], 'ancestors': [{'id': 'D056831', 'term': 'Coordination Complexes'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D043823', 'term': 'Taxoids'}, {'id': 'D043822', 'term': 'Cyclodecanes'}, {'id': 'D003516', 'term': 'Cycloparaffins'}, {'id': 'D006840', 'term': 'Hydrocarbons, Alicyclic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D004224', 'term': 'Diterpenes'}, {'id': 'D013729', 'term': 'Terpenes'}, {'id': 'D013812', 'term': 'Therapeutics'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 69}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2002-05'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-11', 'completionDateStruct': {'date': '2010-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-11-30', 'studyFirstSubmitDate': '2002-03-08', 'studyFirstSubmitQcDate': '2003-01-26', 'lastUpdatePostDateStruct': {'date': '2016-12-01', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2003-01-27', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2008-01', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Maximum tolerated dose (MTD) as assessed by dose-limiting toxicity within 1 month after completion of study treatment (phase I)', 'timeFrame': 'Up to 1 month'}, {'measure': 'Survival at 2 years (phase II)', 'timeFrame': 'Up to 2 years'}], 'secondaryOutcomes': [{'measure': 'Survival time', 'timeFrame': 'Up to 5 years'}, {'measure': 'Toxicity', 'timeFrame': 'Up to 5 years'}, {'measure': 'Time to progression', 'timeFrame': 'Up to 5 years'}, {'measure': 'Time to local progression', 'timeFrame': 'Up to 5 years'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['stage I non-small cell lung cancer', 'stage II non-small cell lung cancer', 'stage IIIA non-small cell lung cancer', 'stage IIIB non-small cell lung cancer'], 'conditions': ['Lung Cancer']}, 'referencesModule': {'references': [{'type': 'RESULT', 'citation': 'Schild S, Graham D, Hillman S, et al.: Survival of patients (pts) treated with high-dose radiotherapy (RT) and concurrent chemotherapy for unresectable non-small cell lung cancer (NSCLC). [Abstract] J Clin Oncol 27 (Suppl 15): A-7544, 2009.'}, {'pmid': '16730134', 'type': 'RESULT', 'citation': 'Schild SE, McGinnis WL, Graham D, Hillman S, Fitch TR, Northfelt D, Garces YI, Shahidi H, Tschetter LK, Schaefer PL, Adjei A, Jett J. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1106-11. doi: 10.1016/j.ijrobp.2006.02.046. Epub 2006 May 26.'}, {'pmid': '28089762', 'type': 'DERIVED', 'citation': 'Schild SE, Hillman SL, Tan AD, Ross HJ, McGinnis WL, Garces YA, Graham DL, Adjei AA, Jett JR; Mayo Clinic, North Central Cancer Treatment Group. Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol. 2017 Apr;12(4):697-703. doi: 10.1016/j.jtho.2016.12.021. Epub 2017 Jan 12.'}]}, 'descriptionModule': {'briefSummary': 'RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells.\n\nPURPOSE: This phase I/II trial is studying the side effects and best dose of radiation therapy when given with combination chemotherapy and to see how well they work in treating patients with non-small cell lung cancer that cannot be surgically removed.', 'detailedDescription': 'OBJECTIVES:\n\n* Determine the maximum tolerated dose of radiotherapy in combination with carboplatin and paclitaxel in patients with unresectable non-small cell lung cancer.\n* Determine the 2-year survival of patients treated with this regimen.\n* Determine the progression-free local control rate in patients treated this regimen.\n* Determine the tolerability of this regimen in these patients.\n* Assess the quality of life of patients treated with this regimen.\n\nOUTLINE: This is a multicenter, dose-escalation study of radiotherapy.\n\nPatients undergo radiotherapy\\* once daily 5 days a week for 7 weeks and 2 days (a total of 37 fractions). Patients concurrently receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes once weekly for 7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nNOTE: \\*No prophylactic nodal radiotherapy is administered\n\nCohorts of 3-6 patients receive escalating doses of radiotherapy until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 12 additional patients are treated at that dose level in the phase II portion of the study.\n\nBeginning 3 weeks after completion of radiotherapy, patients receive paclitaxel and carboplatin as above. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.\n\nQuality of life is assessed at baseline, once during the last week of radiotherapy, and then every 3 months for 2 years.\n\nPatients are followed at 3 weeks, every 3 months for 21 months, and then every 6 months for 3 years.\n\nPROJECTED ACCRUAL: A total of 90 patients will be accrued for this study.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)\n\n * Stage I, II, or III NSCLC that is unresectable due to tumor extent or other medical reasons\n* Measurable disease\n* Tumor must not exceed volume that would require radiation volumes greater than those allowed on this study\n* No more than blunting of the costophrenic angle on chest x-ray due to pleural effusions\n* No more than small effusions seen on chest CT scan only\n* No supraclavicular adenopathy\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 18 and over\n\nPerformance status:\n\n* ECOG 0-1\n\nLife expectancy:\n\n* At least 12 weeks\n\nHematopoietic:\n\n* Absolute neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n\nHepatic:\n\n* Total bilirubin no greater than 1.5 times upper limit of normal (ULN) OR\n* Direct bilirubin no greater than 1.5 times ULN\n* AST no greater than 3 times ULN\n\nRenal:\n\n* Creatinine clearance at least 40 mL/min\n\nCardiovascular:\n\n* No New York Heart Association class III or IV heart disease\n\nPulmonary:\n\n* FEV\\_1 at least 1 L or 35% of predicted\n\nOther:\n\n* No grade 2 or greater peripheral neuropathy\n* No weight loss of 10% or more within the past 3 months\n* No uncontrolled infection\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinoma (carcinoma in situ), or localized prostate cancer\n* No other severe underlying disease that would preclude study participation\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic:\n\n* No prior biologic therapy for NSCLC\n* No concurrent biologic therapy\n* No concurrent prophylactic filgrastim (G-CSF)\n\nChemotherapy:\n\n* No prior chemotherapy for NSCLC\n* No other concurrent chemotherapy\n\nEndocrine therapy:\n\n* No prior endocrine therapy for NSCLC\n\nRadiotherapy:\n\n* No prior radiotherapy for NSCLC\n\nSurgery:\n\n* No prior surgery for NSCLC'}, 'identificationModule': {'nctId': 'NCT00032032', 'briefTitle': 'Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer', 'organization': {'class': 'OTHER', 'fullName': 'Alliance for Clinical Trials in Oncology'}, 'officialTitle': 'Phase I/II Study Of Concurrent Chemotherapy And Escalating Doses Of Radiotherapy (RT) For Unresectable Non-Small Cell Lung Cancer (NSCLC) Using A New RT Paradigm', 'orgStudyIdInfo': {'id': 'NCCTG-N0028'}, 'secondaryIdInfos': [{'id': 'NCI-2012-02458', 'type': 'REGISTRY', 'domain': 'CTRP (Clinical Trials Reporting System)'}, {'id': 'CDR0000069250', 'type': 'REGISTRY', 'domain': 'PDQ (Physician Data Query)'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'radiotherapy + paclitaxel + carboplatin', 'description': 'Patients undergo radiotherapy once daily 5 days a week for 7 weeks and 2 days (a total of 37 fractions). Patients concurrently receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes once weekly for 7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nBeginning 3 weeks after completion of radiotherapy, patients receive paclitaxel and carboplatin as above. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.\n\nQuality of life is assessed at baseline, once during the last week of radiotherapy, and then every 3 months for 2 years.\n\nPatients are followed at 3 weeks, every 3 months for 21 months, and then every 6 months for 3 years.', 'interventionNames': ['Drug: carboplatin', 'Drug: paclitaxel', 'Radiation: radiation therapy']}], 'interventions': [{'name': 'carboplatin', 'type': 'DRUG', 'armGroupLabels': ['radiotherapy + paclitaxel + carboplatin']}, {'name': 'paclitaxel', 'type': 'DRUG', 'armGroupLabels': ['radiotherapy + paclitaxel + carboplatin']}, {'name': 'radiation therapy', 'type': 'RADIATION', 'armGroupLabels': ['radiotherapy + paclitaxel + carboplatin']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85259-5499', 'city': 'Scottsdale', 'state': 'Arizona', 'country': 'United States', 'facility': 'Mayo Clinic Scottsdale', 'geoPoint': {'lat': 33.50921, 'lon': -111.89903}}, {'zip': '32224', 'city': 'Jacksonville', 'state': 'Florida', 'country': 'United States', 'facility': 'Mayo Clinic - Jacksonville', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'zip': '50010', 'city': 'Ames', 'state': 'Iowa', 'country': 'United States', 'facility': 'McFarland Clinic, PC', 'geoPoint': {'lat': 42.03471, 'lon': -93.61994}}, {'zip': '50307', 'city': 'Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'Mercy Capitol Hospital', 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'zip': '50309', 'city': 'Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'CCOP - Iowa Oncology Research Association', 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'zip': '50309', 'city': 'Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'John Stoddard Cancer Center at Iowa Methodist Medical Center', 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'zip': '50309', 'city': 'Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'Medical Oncology and Hematology Associates at John Stoddard Cancer Center', 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'zip': '50314', 'city': 'Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'Medical Oncology and Hematology Associates at Mercy Cancer Center', 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'zip': '50314', 'city': 'Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'Mercy Cancer Center at Mercy Medical Center - Des Moines', 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'zip': '50316', 'city': 'Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'John Stoddard Cancer Center at Iowa Lutheran Hospital', 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'zip': '51101', 'city': 'Sioux City', 'state': 'Iowa', 'country': 'United States', 'facility': 'Siouxland Hematology-Oncology Associates, LLP', 'geoPoint': {'lat': 42.49999, 'lon': -96.40031}}, {'zip': '51104', 'city': 'Sioux City', 'state': 'Iowa', 'country': 'United States', 'facility': 'Mercy Medical Center - Sioux City', 'geoPoint': {'lat': 42.49999, 'lon': -96.40031}}, {'zip': '51104', 'city': 'Sioux City', 'state': 'Iowa', 'country': 'United States', 'facility': "St. Luke's Regional Medical Center", 'geoPoint': {'lat': 42.49999, 'lon': -96.40031}}, {'zip': '49221', 'city': 'Adrian', 'state': 'Michigan', 'country': 'United States', 'facility': 'Hickman Cancer Center at Bixby Medical Center', 'geoPoint': {'lat': 41.89755, 'lon': -84.03717}}, {'zip': '48144', 'city': 'Lambertville', 'state': 'Michigan', 'country': 'United States', 'facility': 'Haematology-Oncology Associates of Ohio and Michigan, PC', 'geoPoint': {'lat': 41.76588, 'lon': -83.62799}}, {'zip': '48162', 'city': 'Monroe', 'state': 'Michigan', 'country': 'United States', 'facility': 'Community Cancer Center of Monroe', 'geoPoint': {'lat': 41.91643, 'lon': -83.39771}}, {'zip': '48162', 'city': 'Monroe', 'state': 'Michigan', 'country': 'United States', 'facility': 'Mercy Memorial Hospital - Monroe', 'geoPoint': {'lat': 41.91643, 'lon': -83.39771}}, {'zip': '56601', 'city': 'Bemidji', 'state': 'Minnesota', 'country': 'United States', 'facility': 'MeritCare Bemidji', 'geoPoint': {'lat': 47.47356, 'lon': -94.88028}}, {'zip': '55905', 'city': 'Rochester', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Mayo Clinic Cancer Center', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}, {'zip': '68106', 'city': 'Omaha', 'state': 'Nebraska', 'country': 'United States', 'facility': 'CCOP - Missouri Valley Cancer Consortium', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '68122', 'city': 'Omaha', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Immanuel Medical Center', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '68124', 'city': 'Omaha', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Alegant Health Cancer Center at Bergan Mercy Medical Center', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '68131-2197', 'city': 'Omaha', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Creighton University Medical Center', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '58501', 'city': 'Bismarck', 'state': 'North Dakota', 'country': 'United States', 'facility': 'Bismarck Cancer Center', 'geoPoint': {'lat': 46.80833, 'lon': -100.78374}}, {'zip': '58501', 'city': 'Bismarck', 'state': 'North Dakota', 'country': 'United States', 'facility': 'Medcenter One Hospital Cancer Care Center', 'geoPoint': {'lat': 46.80833, 'lon': -100.78374}}, {'zip': '58501', 'city': 'Bismarck', 'state': 'North Dakota', 'country': 'United States', 'facility': 'Mid Dakota Clinic, PC', 'geoPoint': {'lat': 46.80833, 'lon': -100.78374}}, {'zip': '58502', 'city': 'Bismarck', 'state': 'North Dakota', 'country': 'United States', 'facility': 'St. Alexius Medical Center Cancer Center', 'geoPoint': {'lat': 46.80833, 'lon': -100.78374}}, {'zip': '58122', 'city': 'Fargo', 'state': 'North Dakota', 'country': 'United States', 'facility': 'CCOP - MeritCare Hospital', 'geoPoint': {'lat': 46.87719, 'lon': -96.7898}}, {'zip': '58122', 'city': 'Fargo', 'state': 'North Dakota', 'country': 'United States', 'facility': 'MeritCare Broadway', 'geoPoint': {'lat': 46.87719, 'lon': -96.7898}}, {'zip': '43402', 'city': 'Bowling Green', 'state': 'Ohio', 'country': 'United States', 'facility': 'Wood County Oncology Center', 'geoPoint': {'lat': 41.37477, 'lon': -83.65132}}, {'zip': '43420', 'city': 'Fremont', 'state': 'Ohio', 'country': 'United States', 'facility': 'Fremont Memorial Hospital', 'geoPoint': {'lat': 41.35033, 'lon': -83.12186}}, {'zip': '45804', 'city': 'Lima', 'state': 'Ohio', 'country': 'United States', 'facility': 'Lima Memorial Hospital', 'geoPoint': {'lat': 40.74255, 'lon': -84.10523}}, {'zip': '43537', 'city': 'Maumee', 'state': 'Ohio', 'country': 'United States', 'facility': 'Northwest Ohio Oncology Center', 'geoPoint': {'lat': 41.56283, 'lon': -83.65382}}, {'zip': '43537', 'city': 'Maumee', 'state': 'Ohio', 'country': 'United States', 'facility': "St. Luke's Hospital", 'geoPoint': {'lat': 41.56283, 'lon': -83.65382}}, {'zip': '43616', 'city': 'Oregon', 'state': 'Ohio', 'country': 'United States', 'facility': 'St. Charles Mercy Hospital', 'geoPoint': {'lat': 41.64366, 'lon': -83.48688}}, {'zip': '43616', 'city': 'Oregon', 'state': 'Ohio', 'country': 'United States', 'facility': 'Toledo Clinic - Oregon', 'geoPoint': {'lat': 41.64366, 'lon': -83.48688}}, {'zip': '44870', 'city': 'Sandusky', 'state': 'Ohio', 'country': 'United States', 'facility': 'Firelands Regional Medical Center', 'geoPoint': {'lat': 41.44894, 'lon': -82.70796}}, {'zip': '44870', 'city': 'Sandusky', 'state': 'Ohio', 'country': 'United States', 'facility': 'North Coast Cancer Care, Incorporated', 'geoPoint': {'lat': 41.44894, 'lon': -82.70796}}, {'zip': '43560', 'city': 'Sylvania', 'state': 'Ohio', 'country': 'United States', 'facility': 'Flower Hospital Cancer Center', 'geoPoint': {'lat': 41.71894, 'lon': -83.71299}}, {'zip': '44883', 'city': 'Tiffin', 'state': 'Ohio', 'country': 'United States', 'facility': 'Mercy Hospital of Tiffin', 'geoPoint': {'lat': 41.1145, 'lon': -83.17797}}, {'zip': '43606', 'city': 'Toledo', 'state': 'Ohio', 'country': 'United States', 'facility': 'Toledo Hospital', 'geoPoint': {'lat': 41.66394, 'lon': -83.55521}}, {'zip': '43608', 'city': 'Toledo', 'state': 'Ohio', 'country': 'United States', 'facility': 'St. Vincent Mercy Medical Center', 'geoPoint': {'lat': 41.66394, 'lon': -83.55521}}, {'zip': '43614', 'city': 'Toledo', 'state': 'Ohio', 'country': 'United States', 'facility': 'Medical University of Ohio Cancer Center', 'geoPoint': {'lat': 41.66394, 'lon': -83.55521}}, {'zip': '43617', 'city': 'Toledo', 'state': 'Ohio', 'country': 'United States', 'facility': 'CCOP - Toledo Community Hospital', 'geoPoint': {'lat': 41.66394, 'lon': -83.55521}}, {'zip': '43623', 'city': 'Toledo', 'state': 'Ohio', 'country': 'United States', 'facility': 'Toledo Clinic, Incorporated - Main Clinic', 'geoPoint': {'lat': 41.66394, 'lon': -83.55521}}, {'zip': '43567', 'city': 'Wauseon', 'state': 'Ohio', 'country': 'United States', 'facility': 'Fulton County Health Center', 'geoPoint': {'lat': 41.54922, 'lon': -84.14161}}, {'zip': '57105', 'city': 'Sioux Falls', 'state': 'South Dakota', 'country': 'United States', 'facility': 'Avera Cancer Institute', 'geoPoint': {'lat': 43.54369, 'lon': -96.72796}}, {'zip': '57105', 'city': 'Sioux Falls', 'state': 'South Dakota', 'country': 'United States', 'facility': 'Medical X-Ray Center, PC', 'geoPoint': {'lat': 43.54369, 'lon': -96.72796}}, {'zip': '57117-5039', 'city': 'Sioux Falls', 'state': 'South Dakota', 'country': 'United States', 'facility': 'Sanford Cancer Center at Sanford USD Medical Center', 'geoPoint': {'lat': 43.54369, 'lon': -96.72796}}, {'zip': '22401', 'city': 'Fredericksburg', 'state': 'Virginia', 'country': 'United States', 'facility': 'Fredericksburg Oncology, Incorporated', 'geoPoint': {'lat': 38.30318, 'lon': -77.46054}}, {'zip': '54601', 'city': 'La Crosse', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'Franciscan Skemp Healthcare - La Crosse Campus', 'geoPoint': {'lat': 43.80136, 'lon': -91.23958}}], 'overallOfficials': [{'name': 'Steven E. Schild, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'Mayo Clinic'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Alliance for Clinical Trials in Oncology', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}], 'responsibleParty': {'type': 'SPONSOR'}}}}